Olpres
Generic Name
Olmesartan Medoxomil
Manufacturer
ACI Limited
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| olpres 10 mg tablet | ৳ 5.00 | ৳ 50.00 |
Description
Overview of the medicine
Olmesartan Medoxomil is an angiotensin II receptor blocker (ARB) used to treat high blood pressure (hypertension). It helps to relax blood vessels, allowing blood to flow more easily and thereby lowering blood pressure.
Uses & Indications
Dosage
Adults
The usual starting dose is 10 mg once daily. The dose can be increased to 20 mg once daily after 2 weeks if blood pressure is not adequately controlled. The maximum recommended dose is 40 mg once daily.
Elderly
No initial dose adjustment is generally required for elderly patients. Close monitoring of blood pressure and renal function is recommended.
Renal_impairment
For patients with moderate to severe renal impairment (creatinine clearance <40 mL/min), the maximum dose is 20 mg once daily. Not recommended for patients on dialysis.
How to Take
Olpres tablets should be taken orally once daily, with or without food. It is recommended to take the tablet at approximately the same time each day.
Mechanism of Action
Olmesartan Medoxomil is a prodrug that is rapidly converted to its active metabolite, olmesartan, in the gastrointestinal tract. Olmesartan selectively blocks the binding of angiotensin II to the AT1 receptor, which is found in many tissues, including vascular smooth muscle and the adrenal gland. By blocking this binding, olmesartan inhibits the vasoconstrictive and aldosterone-secreting effects of angiotensin II, leading to vasodilation, decreased peripheral resistance, and reduced blood pressure.
Pharmacokinetics
Onset
Significant blood pressure reduction typically observed within 2 weeks, with full antihypertensive effect developing over 8 weeks.
Excretion
Approximately 50-65% is excreted unchanged in bile via the liver, and 35-50% is excreted unchanged in urine via the kidneys.
Half life
The elimination half-life of olmesartan is approximately 13 hours.
Absorption
Rapidly and completely absorbed from the gastrointestinal tract and hydrolyzed to active olmesartan. Bioavailability is approximately 26%. Peak plasma concentration (Cmax) is reached within 1 to 2 hours.
Metabolism
Olmesartan Medoxomil is completely and rapidly converted to olmesartan by esterases in the gut wall and during first-pass hepatic metabolism. Olmesartan is not further metabolized.
Side Effects
Contraindications
- Hypersensitivity to olmesartan medoxomil or any other component of the product.
- Pregnancy (especially during the second and third trimesters) due to risk of fetal injury and death.
- Concomitant use with aliskiren in patients with diabetes or moderate to severe renal impairment (GFR <60 mL/min/1.73 m2).
- Biliary obstruction.
Drug Interactions
Lithium
Increased serum lithium concentrations and toxicity have been reported with concomitant use of ARBs. Monitor serum lithium levels carefully.
Aliskiren
Concomitant use with aliskiren is contraindicated in patients with diabetes or moderate to severe renal impairment due to increased risk of hyperkalemia, hypotension, and renal impairment.
Diuretics
Concomitant use with diuretics, especially in volume-depleted patients, may result in excessive blood pressure reduction (hypotension).
NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)
May reduce the antihypertensive effect of olmesartan and increase the risk of renal function deterioration, including acute renal failure, especially in elderly or volume-depleted patients. Monitor renal function periodically.
Storage
Store below 30°C in a dry place, away from direct light and moisture. Keep out of reach of children.
Overdose
Symptoms of overdose typically include hypotension (low blood pressure) and possibly tachycardia (fast heart rate) or bradycardia (slow heart rate). Management involves supportive care, including intravenous fluid administration to correct hypotension. Hemodialysis is not effective in removing olmesartan.
Pregnancy & Lactation
Olpres is contraindicated during pregnancy, especially during the second and third trimesters, as it can cause injury and death to the developing fetus. Women of childbearing potential should use effective contraception. It is not recommended during lactation, as it is unknown whether olmesartan is excreted in human milk.
Side Effects
Contraindications
- Hypersensitivity to olmesartan medoxomil or any other component of the product.
- Pregnancy (especially during the second and third trimesters) due to risk of fetal injury and death.
- Concomitant use with aliskiren in patients with diabetes or moderate to severe renal impairment (GFR <60 mL/min/1.73 m2).
- Biliary obstruction.
Drug Interactions
Lithium
Increased serum lithium concentrations and toxicity have been reported with concomitant use of ARBs. Monitor serum lithium levels carefully.
Aliskiren
Concomitant use with aliskiren is contraindicated in patients with diabetes or moderate to severe renal impairment due to increased risk of hyperkalemia, hypotension, and renal impairment.
Diuretics
Concomitant use with diuretics, especially in volume-depleted patients, may result in excessive blood pressure reduction (hypotension).
NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)
May reduce the antihypertensive effect of olmesartan and increase the risk of renal function deterioration, including acute renal failure, especially in elderly or volume-depleted patients. Monitor renal function periodically.
Storage
Store below 30°C in a dry place, away from direct light and moisture. Keep out of reach of children.
Overdose
Symptoms of overdose typically include hypotension (low blood pressure) and possibly tachycardia (fast heart rate) or bradycardia (slow heart rate). Management involves supportive care, including intravenous fluid administration to correct hypotension. Hemodialysis is not effective in removing olmesartan.
Pregnancy & Lactation
Olpres is contraindicated during pregnancy, especially during the second and third trimesters, as it can cause injury and death to the developing fetus. Women of childbearing potential should use effective contraception. It is not recommended during lactation, as it is unknown whether olmesartan is excreted in human milk.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Refer to the manufacturer's packaging for specific shelf life, typically 24-36 months from the manufacturing date.
Availability
Pharmacies, Hospitals
Approval Status
Approved by FDA and DGDA
Patent Status
Off-patent
Clinical Trials
Olmesartan Medoxomil has undergone extensive clinical trials demonstrating its efficacy and safety in treating hypertension. Post-marketing surveillance continues to monitor long-term outcomes and rare adverse events.
Lab Monitoring
- Serum creatinine and blood urea nitrogen (BUN) to monitor renal function, especially at initiation and periodically thereafter.
- Serum potassium levels, particularly in patients with renal impairment or those taking potassium-sparing diuretics or potassium supplements.
- Blood pressure monitoring regularly.
Doctor Notes
- Ensure regular monitoring of renal function and serum electrolyte levels (especially potassium) in patients, particularly those at higher risk.
- Advise patients about the potential for dizziness and symptomatic hypotension, especially at the initiation of therapy or during dose escalation.
- Caution with concomitant use of NSAIDs, as they may impair the antihypertensive effect and worsen renal function.
- Emphasize the importance of contraception for women of childbearing potential due to the black box warning on fetal toxicity.
Patient Guidelines
- Take Olpres exactly as prescribed by your doctor.
- Do not stop taking this medicine without consulting your doctor, even if you feel better.
- Monitor your blood pressure regularly at home, as advised by your doctor.
- Inform your doctor about all other medications, supplements, and herbal products you are taking.
- Report any unusual symptoms, especially swelling of the face, lips, tongue, or throat (angioedema), or severe dizziness.
Missed Dose Advice
If you miss a dose, take it as soon as you remember. However, if it is almost time for your next dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed one.
Driving Precautions
Olpres may cause dizziness or lightheadedness, especially when starting treatment or increasing the dose. Patients should be cautious when driving or operating machinery until they know how the medication affects them.
Lifestyle Advice
- Adopt a healthy lifestyle including a balanced diet rich in fruits, vegetables, and whole grains, and low in saturated fats and cholesterol.
- Engage in regular physical activity, such as brisk walking, for at least 30 minutes most days of the week.
- Limit sodium (salt) intake in your diet.
- Avoid smoking and limit alcohol consumption, as these can negatively impact blood pressure.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.
Other Medicines in Olpres Brand
Other medicines available under the same brand name
